Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

CDDO-Me Protects Normal Lung and Breast Epithelial Cells but Not Cancer Cells from Radiation

Open access

Abstract

Although radiation therapy is commonly used for treatment for many human diseases including cancer, ionizing radiation produces reactive oxygen species that can damage both cancer and healthy cells. Synthetic triterpenoids, including CDDO-Me, act as anti-inflammatory and antioxidant modulators primarily by inducing the transcription factor Nrf2 to activate downstream genes containing antioxidant response elements (AREs). In the present series of experiments, we determined if CDDO-Me can be used as a radioprotector in normal non-cancerous human lung and breast epithelial cells, in comparison to lung and breast cancer cell lines. A panel of normal non-cancerous, partially cancer progressed, and cancer cell lines from both lung and breast tissue was exposed to gamma radiation with and without pre-treatment with CDDO-Me. CDDO-Me was an effective radioprotector when given ∼18 hours before radiation in epithelial cells (average dose modifying factor (DMF) = 1.3), and Nrf2 function was necessary for CDDO-Me to exert these radioprotective effects. CDDO-Me did not protect cancer lines tested from radiation-induced cytotoxicity, nor did it protect experimentally transformed human bronchial epithelial cells (HBECs) with progressive oncogenic manipulations. CDDO-Me also protected human lymphocytes against radiation-induced DNA damage. A therapeutic window exists in which CDDO-Me protects normal cells from radiation by activating the Nrf2 pathway, but does not protect experimentally transformed or cancer cell lines. This suggests that use of this oral available, non-toxic class of drug can protect non-cancerous healthy cells during radiotherapy, resulting in better outcomes and less toxicity for patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0115600

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 CDDO-Me activates the Nrf2 antioxidant pathway in epithelial cells. (A) Nrf2 Pathway: Nrf2 is a transcription factor normally bound by its cytoplasmic repressor Keap1, which acts as a molecular oxidative sensor and marks Nrf2 for degradation. When there is an abundance of reactive species in the cells, Nrf2 accumulates in the cytoplasm, eventually undergoing various phosphorylation events to translocate to the nucleus and bind to Antioxidant Response Elements (AREs) in the genome, resulting in the transcription of multiple antioxidative and cyto-protective genes. CDDO-Me acts by facilitating the dissociation between Keap1 and Nrf2, leading to Nrf2 activation. (B) Chemical structure of CDDO-Me: Oleana-1,9(11)-dien-28-oicacid, 2-cyano-3,12-dioxo-, methyl ester (RTA-402; bardoxolone-methyl). (C, D) CDDO-Me increases expression of ARE-driven luciferase 18 hours after drug treatment in HBEC 3KT and HME1, respectively. Firefly ARE-luciferase normalized to renilla control (RLU). Mean ± SEM of 6 replicates, *p<0.05 using paired t-test (between DMSO and drug). (E) CDDO-Me 10 nM activates heme oxygenase-1 (HO1, band observed at ∼32 kDa), NADPH dehydrogenase quinone (NQO1, band observed at ∼30 kDa), and peroxiredoxin (PRX1, band observed at ∼20 kDa), all downstream targets of Nrf2/ARE and peaking at approximately18 hours after treatment in HBEC 3KT.
Figure 1 CDDO-Me activates the Nrf2 antioxidant pathway in epithelial cells. (A) Nrf2 Pathway: Nrf2 is a transcription factor normally bound by its cytoplasmic repressor Keap1, which acts as a molecular oxidative sensor and marks Nrf2 for degradation. When there is an abundance of reactive species in the cells, Nrf2 accumulates in the cytoplasm, eventually undergoing various phosphorylation events to translocate to the nucleus and bind to Antioxidant Response Elements (AREs) in the genome, resulting in the transcription of multiple antioxidative and cyto-protective genes. CDDO-Me acts by facilitating the dissociation between Keap1 and Nrf2, leading to Nrf2 activation. (B) Chemical structure of CDDO-Me: Oleana-1,9(11)-dien-28-oicacid, 2-cyano-3,12-dioxo-, methyl ester (RTA-402; bardoxolone-methyl). (C, D) CDDO-Me increases expression of ARE-driven luciferase 18 hours after drug treatment in HBEC 3KT and HME1, respectively. Firefly ARE-luciferase normalized to renilla control (RLU). Mean ± SEM of 6 replicates, *p<0.05 using paired t-test (between DMSO and drug). (E) CDDO-Me 10 nM activates heme oxygenase-1 (HO1, band observed at ∼32 kDa), NADPH dehydrogenase quinone (NQO1, band observed at ∼30 kDa), and peroxiredoxin (PRX1, band observed at ∼20 kDa), all downstream targets of Nrf2/ARE and peaking at approximately18 hours after treatment in HBEC 3KT.CC BY · PubMed Central
Figure 2 Pre-treatment with CDDO-Me decreases IR-induced DNA damage in a variety of non-cancerous cells. CDDO-Me decreases radiation-induced DNA damage in the alkaline comet assay in bronchial and mammary epithelial cells as well as human lymphocytes. (A) HBEC 3KT, (B) HME1, and (C) PBMCs were treated with CDDO-Me 18 hours prior to IR, then mounted on slides 30 min post-IR. Data analyzed and calculated using Open Comet software [tail moment = tail length x tail DNA percentage]. Mean ± SEM of >50 cells per condition, *p<0.05 using t-test (compared to 3 Gy DMSO). **p<0.01, using T-test (compared to 0 Gy DMSO).
Figure 2 Pre-treatment with CDDO-Me decreases IR-induced DNA damage in a variety of non-cancerous cells. CDDO-Me decreases radiation-induced DNA damage in the alkaline comet assay in bronchial and mammary epithelial cells as well as human lymphocytes. (A) HBEC 3KT, (B) HME1, and (C) PBMCs were treated with CDDO-Me 18 hours prior to IR, then mounted on slides 30 min post-IR. Data analyzed and calculated using Open Comet software [tail moment = tail length x tail DNA percentage]. Mean ± SEM of >50 cells per condition, *p<0.05 using t-test (compared to 3 Gy DMSO). **p<0.01, using T-test (compared to 0 Gy DMSO).CC BY · PubMed Central
Figure 3 CDDO-Me is a potent radiation countermeasure in bronchial and breast epithelial cells, and Nrf2 knockdown abrogates these radioprotective effects. (A) Normal breast and lung epithelia are radioprotected at multiple doses of CDDO-Me. Cells were treated with drug 18 hours before exposure to 3 Gy gamma IR, then seeded immediately into clonogenicity. Colonies grown for ∼14 days before fixation with 6% glutaraldehyde/0.5% crystal violet stain. Mean ± SEM of four experiments seeded in triplicate, *p<0.05, **p<0.001 using t-test (compared to DMSO at 3 Gy). (B, C) HMEC and (D) HBEC cells pre-treated with 10 nM CDDO-Me have a significant increase in clonogenic survival. (E) HBEC 3KT with sh-Nrf2 see no radioprotection when pre-treated with CDDO-Me. Clonogenic survivals, mean ± SEM with linear-quadratic fit curve of four experiments seeded in triplicate. (F) Nrf2 knockdown cells have a ∼90% decrease of Nrf2 activity compared to non-silencing control, with diminished basal and CDDO-Me-induced ARE-luciferase activity. Mean ± SEM of six replicates, *p<0.05, **p<0.01, t-test (compared to non-silencing control).
Figure 3 CDDO-Me is a potent radiation countermeasure in bronchial and breast epithelial cells, and Nrf2 knockdown abrogates these radioprotective effects. (A) Normal breast and lung epithelia are radioprotected at multiple doses of CDDO-Me. Cells were treated with drug 18 hours before exposure to 3 Gy gamma IR, then seeded immediately into clonogenicity. Colonies grown for ∼14 days before fixation with 6% glutaraldehyde/0.5% crystal violet stain. Mean ± SEM of four experiments seeded in triplicate, *p<0.05, **p<0.001 using t-test (compared to DMSO at 3 Gy). (B, C) HMEC and (D) HBEC cells pre-treated with 10 nM CDDO-Me have a significant increase in clonogenic survival. (E) HBEC 3KT with sh-Nrf2 see no radioprotection when pre-treated with CDDO-Me. Clonogenic survivals, mean ± SEM with linear-quadratic fit curve of four experiments seeded in triplicate. (F) Nrf2 knockdown cells have a ∼90% decrease of Nrf2 activity compared to non-silencing control, with diminished basal and CDDO-Me-induced ARE-luciferase activity. Mean ± SEM of six replicates, *p<0.05, **p<0.01, t-test (compared to non-silencing control).CC BY · PubMed Central
Figure 4 CDDO-Me radioprotection decreases with progressive oncogenic manipulations in HBECs and in a matched NSCLC line. Isogenic oncogenic progression in HBEC 3KT. Immortalized HBECs with (A) lenti-KRas V12, (B) lenti-KRas V12 and shp53 knockdown, and (C) lenti-KRas V12, shp53, and myc overexpression. Only lenti-KRas V12 cells are still moderately protected by CDDO-Me, but further oncogenic changes eliminate the radioprotective effects of CDDO-Me. (D) HBEC 30KT are protected by CDDO-Me. (E) HCC 4017, a NSCLC isolated from the same patient from which HBEC 30KT was derived, are unprotected by CDDO-Me. (F) Increasing concentrations to 50 nM still enhances clonogenic survival of HBEC 30KT, but actually seems to decrease survival in HCC 4017 after 3 Gy radiation. Mean ± SEM of three experiments seeded in triplicate, **p<0.01, t-test (compared to DMSO at 3 Gy).
Figure 4 CDDO-Me radioprotection decreases with progressive oncogenic manipulations in HBECs and in a matched NSCLC line. Isogenic oncogenic progression in HBEC 3KT. Immortalized HBECs with (A) lenti-KRas V12, (B) lenti-KRas V12 and shp53 knockdown, and (C) lenti-KRas V12, shp53, and myc overexpression. Only lenti-KRas V12 cells are still moderately protected by CDDO-Me, but further oncogenic changes eliminate the radioprotective effects of CDDO-Me. (D) HBEC 30KT are protected by CDDO-Me. (E) HCC 4017, a NSCLC isolated from the same patient from which HBEC 30KT was derived, are unprotected by CDDO-Me. (F) Increasing concentrations to 50 nM still enhances clonogenic survival of HBEC 30KT, but actually seems to decrease survival in HCC 4017 after 3 Gy radiation. Mean ± SEM of three experiments seeded in triplicate, **p<0.01, t-test (compared to DMSO at 3 Gy).CC BY · PubMed Central
Figure 5 NSCLC and breast cancer cells are not protected with CDDO-Me. Clonogenic survivals show that (A) A549, (B) H2009, and (C) HCC 2429 are not protected when pretreated with the same concentration of CDDO-Me (10 nM) that protected HBEC cells. (E) Even higher concentrations of CDDO-Me are not protective of cancer cells after 3 Gy radiation, including MDA-MB-231 breast cancer line. However, 150 nM CDDO-Me significantly decreases the clonogenic survival of MDA-MD-231 cells after exposure to 3 Gy radiation. Mean ± SEM of three experiments seeded in triplicate, **p<0.01, t-test (compared to DMSO at 3 Gy).
Figure 5 NSCLC and breast cancer cells are not protected with CDDO-Me. Clonogenic survivals show that (A) A549, (B) H2009, and (C) HCC 2429 are not protected when pretreated with the same concentration of CDDO-Me (10 nM) that protected HBEC cells. (E) Even higher concentrations of CDDO-Me are not protective of cancer cells after 3 Gy radiation, including MDA-MB-231 breast cancer line. However, 150 nM CDDO-Me significantly decreases the clonogenic survival of MDA-MD-231 cells after exposure to 3 Gy radiation. Mean ± SEM of three experiments seeded in triplicate, **p<0.01, t-test (compared to DMSO at 3 Gy).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 19

Metadata

Authors
El-Ashmawy, M., Delgado, O., Cardentey, A., Wright, W. E., & Shay, J. W.
Affiliations
  • The University of Texas Southwestern Medical Center (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • King Abdulaziz University (SA)
Corresponding author
Shay, Jerry W.
Venue
PLoS ONE
Published
2014-12-23
Volume
9
Issue
12
Pages
e115600
ISSN
1932-6203 (ISSN-L)
OpenAlex
W1977648215
Cited by
19
References
39
Citations by year
2025: 2 · 2023: 1 · 2022: 3 · 2021: 1 · 2020: 2 · 2019: 3 · 2017: 1 · 2016: 1 · 2015: 5
FWCI
1.83
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
Funders
  • Howard Hughes Medical Institute
  • National Aeronautics and Space Administration (NNX09AU95G)
  • University of Texas Southwestern Medical Center (P50CA70907)
  • National Institutes of Health
  • National Cancer Institute ((P50-CA70907, P50CA070907, SPORE P50CA70907)
  • National Center for Research Resources (C06 RR 30414, C06RR030414)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Effects of Radiation Exposure
  • Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
Keywords
bardoxolone methyl, synthetic triterpenoids, radiation protection, Nrf2, antioxidant response element, gamma radiation, lung epithelial cells, breast epithelial cells, radiation-induced DNA damage, dose modification factor, radiotherapy toxicity, human bronchial epithelial cells, lymphocytes, reactive oxygen species
MeSH terms
Animals, Antioxidants, Breast, Breast Neoplasms, Cell Line, DNA Damage, Epithelial Cells, Female, Humans, Lung, Lung Neoplasms, Oleanolic Acid, Radiation-Protective Agents, Signal Transduction, Cell Line, Tumor, NF-E2-Related Factor 2, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CDDO-Me Protects Normal Lung and Breast Epithelial Cells but Not Cancer Cells from Radiation. https://app.cochat.ai/papers/10.1371/journal.pone.0115600
The paper
El-Ashmawy, M., Delgado, O., Cardentey, A., Wright, W. E., & Shay, J. W. (2014). CDDO-Me Protects Normal Lung and Breast Epithelial Cells but Not Cancer Cells from Radiation. PLoS ONE. https://doi.org/10.1371/journal.pone.0115600

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.